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A B S T R A C T
The causal role of human papillomavirus (HPV) in all cancers of the uterine cervix has been firmly established bio-
logically and epidemiologically. Most cancers of both the vulva and the vagina are also induced by HPV. Papilloma-
viruses are perfectly adapted to their natural host tissue, the differentiating epithelial cell of skin or mucosae, and exploit
the cellular machinery for their own purposes. The infectious cycle is initiated once the infectious particles reach the
basal layer of the epithelium, where they bind to and enter the cells. The critical molecules in the process of virus replica-
tion are the viral proteins E6 and E7, which interact with a number of cellular proteins. In experimental system these in-
teractions have been shown to induce proliferation and eventually immortalization and malignant transformation of
cells. Binding of E7 to pRb activates the E2F transcription factor, which then triggers the expression of proteins necessary
for DNA replication. Unscheduled S-phase would normally lead to apoptosis by the action of p53. However, in HPV-in-
fected cells, this process is counteracted by the viral E6 protein, which targets p53 for proteolytic degradation. Besides
blocking p53 function in regulation of apoptosis, high-risk HPV proteins interact with both extrinsic and intrinsic apop-
totic pathways. As an aberration of virus infection, constant activity of the viral proteins E6 and E7 leads to increasing
genomic instability, accumulation of oncogene mutations, further loss of cell-growth control and ultimately cancer. The
immune system uses innate and adaptive immunity to recognize and combat foreign agents that invade the body, but
these methods are sometimes ineffective against human papillomavirus. HPV has several mechanisms for avoiding the
immune system. Furthermore, HPV infections disrupt cytokine expression with the E6 and E7 oncoproteins, particularly
targeting the expression of interferon genes. Approximately 10% of individuals develop a persistent infection, and it is
this cohort who is at risk of cancer progression, with the development of high-grade precursor lesions and eventually in-
vasive carcinoma.
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Introduction
Genital Human papillomavirus (HPV) infections are
the most common sexually transmitted infections among
women1–3. The immune system effectively repels most
HPV infections, and is associated with strong localized
cell mediated immune responses. However, approxima-
tely ten percent of infected women develop a persistent
infection, with the risk of developing high-grade precur-
sor lesions and eventually invasive carcinoma4,5. The
causal role of HPV in all cancers of the uterine cervix has
been firmly established6–9. An estimated 40–50% of vul-
var cancers and more than 80% of vulvar intraepithelial
lesions have also been associated with HPV. In cancers of
the vagina and their precursor lesions, HPV DNA was
detected in 64% and 91% of cases10. Tumor formation is
not an inevitable consequence of a viral infection; it
rather reflects the multi-step nature of oncogenesis whe-
re each step constitutes an independent (reversible or ir-
reversible) genetic change that cumulatively contributes
to deregulation of the cell cycle, cell growth, and survi-
val8,11,12.
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Human Papillomaviruses
Papillomaviruses (PVs) are a large family of small
double-stranded DNA viruses, which infect basal layer
cells of stratified squamous epithelia (or cells with the
potential for squamous maturation). PVs are considered
primarily epitheliotropic, but corresponding viral genetic
material has been retrieved from a large variety of tis-
sues13. In humans, DNA and mRNA from different HPVs
have been detected not only in the blood of patients suf-
fering from cervical cancer14,15 but also in healthy blood
donors16,17.
Papillomaviruses are classified into genera, species
and types based on their viral genome heterogeneity. At
present, about 170 types have been identified by se-
quences of the gene encoding the major capsid protein
L113,18–20. HPVs can be classified into high or low-risk
types depending upon their oncogenic potential. High-
-risk genotypes 16 and 18 have been associated with 70%
of cervical carcinoma9,21, and about 60% of HPV positive
vulvar and vaginal carcinoma22–24. Low-risk genotypes 6
and 11 have been isolated in over 90% of genital warts25.
HPV genome organization
Virus particles consist of about 7900 base-pairs (7.9
kbp) long circular DNAmolecules wrapped into a protein
shell26. The HPV genome can be functionally divided into
two regions: Upstream Regulatory Region (URR) and
Open Reading Frames (ORFs). URR does not code for
proteins but contains cis-elements required for regula-
tion of gene expression, replication of the genome, and its
packaging into virus particles. ORFs can be divided into
the Early Region (E), necessary for the replication, cellu-
lar transformation, and control of viral transcription,
and the Late Region (L) that codes for the capsid pro-
teins comprising the outer coat of the virus.
Within the Early Regions (E) it is possible to distin-
guish at least six different genes with specific func-
tions19. E1 and E2 genes have an important role in basal
DNA replication. During viral persistence, the immune
system keeps the infection in this state. E2 participates
in the regulation of LCR (low-copy repeats) transcrip-
tions, and decreases the expression of E6 and E7. E4
gene codes for one family of small proteins involved in
the transformation of the host cell by producing alter-
ations of the mitotic signals and interacting with keratin.
E5 decreases intercellular communication, isolates the
transformed cells, interacts with the growth factor’s re-
ceptors, and encourages cellular proliferation. It also
stimulates the expression of E6 and E7. E6 is oncogenic,
stimulating the growth and transformation of the host
cell by inhibiting protein p53’s normal tumor-suppressor
function. E7 also acts as oncogene, inducing cellular pro-
liferation by inhibition of protein pRb. Within the Late
Region (L), it is possible to distinguish the L1 gene,
which codes for the major capsid protein and can form vi-
rus-like particles, and the L2, which codes for the minor
capsid protein27.
Natural history of genital HPV infection
Genital HPV infections are sexually transmitted in-
fections with a lifetime risk of 50–85%, having a peak
prevalence between ages 18 and 3028. Compared with low
transmission probabilities of other sexually transmitted
infections such as human immunodeficiency virus (HIV)
and herpes simplex virus type 2 (HSV-2), the transmis-
sion rate from male to female per intercourse for genital
HPVs has been estimated from 0.4 to 0.829.
Most of these infections clear spontaneously. 75% of
infections clear within a year, and individuals with sub-
optimal immune responses may be at increased risk of
persistent HPV infection and associated malignancy4,6,30.
At present, about 30–40 genotypes of HPV can be iso-
lated in the female genital tract; nevertheless only 12–15
genotypes are usually associated with the development of
carcinoma31–33. Genotypes 16 and 18 have been clearly
shown to be predominant carcinogenic human viral
agents, but in the majority of cases the presence of HPV
alone is insufficient for the development of neoplasm and
different cofactors have been identified: tobacco, alter-
ations of hormonal status, beta-carotene deficiency, con-
ditions of temporary or permanent immunodeficiency,
and other sexually transmitted diseases34,35.
HPV life cycle
HPVs are perfectly adapted to their natural host tis-
sue, the differentiating epithelial cells of skin or mucosa,
and are exploiting the cellular machinery for their own
purposes. HPVs are undergoing a complete life cycle only
in a fully differentiated squamous epithelium. These vi-
ruses infect the basal cell layer, where they establish
their small double-stranded DNA genome as a circular
extra-chromosomal element or episome in the nucleus of
infected cells. Following entry into the suprabasal layer,
the viral genome replicates and in the upper layers of epi-
dermis complete viral particles are released36,37. The ex-
istence of the viral genome in the infected cell is central
to the life cycle of papillomaviruses and their associated
pathologies. Maintenance of the viral genome requires
the activity of E1 (the replicative helicase of papilloma-
virus) and E2, the two viral proteins necessary for repli-
cation of the HPV genome in conjunction with the host
cell DNA replication machinery. As initiator protein E1
acts as both a DNA binding protein to recognize the viral
origin of DNA replication, and subsequently a helicase to
unwind the origin and the DNA ahead of the replication
fork. In lesions containing HPV episomes, the viral E2
protein directly represses early gene expression as part
of a mechanism to regulate copy number. Integration of
viral DNA usually disrupts E2 expression, leading to the
deregulated expression of early viral genes, including E6
and E7. The expression of viral gene products is closely
regulated as the infected basal cell migrates towards the
epithelial surface. Genome amplification, which is neces-
sary for the production of infectious virions, is prevented
until the levels of viral replication proteins rise, and de-
pends on the co-expression of several viral proteins. Viral
persistence leads to clonal progression of the persistently
J. Zekan et al.: Oncogenic Aspects of Human Papillomavirus, Coll. Antropol. 38 (2014) 2: 779–786
780
infected epithelium. Events which are still not com-
pletely understood lead infected cells to malignant trans-
formation.
HPV DNA replication
A viral infection of epidermal stem or transit amplify-
ing cells can result in long term viral persistence, and the
development of carcinogenesis over a significant amount
of time then requires additional cooperating genetic
hits38. The papillomavirus DNA replication depends en-
tirely upon the cellular DNA synthesis machinery. The
problem for the virus is that the necessary cellular DNA
polymerases and replication factors are only available in
dividing cells. However, the virus also replicates in non-
-dividing cells. To solve this problem, HPV encodes pro-
teins that, in the context of the viral life cycle, reactivate
cellular DNA synthesis in non-cycling cells, inhibit apop-
tosis, and delay the differentiation program of the in-
fected keratinocyte, creating an environment permissive
for viral DNA replication39. The precise details by which
this is achieved are not completely understood, but the
relevant viral genes are E6 and E7. Rarely, by-product of
high-risk HPV replication is the deregulation of growth
control in the infected cell and the development of can-
cer30,40,41. The HPV episome is replicated by the viral E1
and E2 proteins together with the host DNA replication
machinery. E1 acts as both a DNA binding protein to rec-
ognize the viral origin, and subsequently a helicase to
unwind the DNA ahead of the replication. Structure-
-function studies have indicated that E1 is a modular
protein comprised of a C-terminal enzymatic domain
with ATPase/helicase activity, a replication origin DNA-
-binding domain located in the center of the protein and
the N-terminal regulatory domain. E1 binds to DNA
with little sequence specificity. In vitro and in vivo, bind-
ing of E1 specifically to the origin is facilitated by its in-
teraction with E2, a transcription/replication factor that
binds with high affinity to sites in the viral origin. As-
sembly of a ternary complex between E1, E2, and the ori-
gin serves as a starting point for the assembly of a larger
E1 complex that has unwinding activity, most likely a
double hexamer necessary for bidirectional unwinding.
E1 interacts with DNA replication factors, including the
polymerase a-primase and the single-stranded binding
protein RPA (Replication Protein A), to promote viral
DNA replication42.
Inhibitors of HPV DNA replication
Interaction between E2 protein and E1 helicase of hu-
man papillomaviruses is essential for the initiation of vi-
ral DNA replication. Research performed by Wang and
colleagues43 led to the identification of the first small
molecule inhibitors of HPV DNA replication. Character-
ization of their mechanism of action has shown that this
class of inhibitors binds to E2 and prevents its interac-
tion with the E1 helicase. These inhibitors defined a pre-
viously unrecognized small-molecule binding pocket on
E2. This class of inhibitors was found to antagonize spe-
cifically the E1-E2 interaction in vivo and to inhibit HPV
DNA replication in transiently infected cells. These re-
sults highlighted for the first time the potential of the
E1-E2 interaction as a small molecule antiviral target for
the treatment of HPV infections44. These inhibitors also
provided a rare example of a class of small molecules that
can antagonize a protein-protein interaction.
Malignant transformation of the
lower genital tract
The female genital tract, a continuum of squamous
epithelium from the vulva to the cervix, is commonly in-
fected by human papillomavirus. The outcome of HPV
infection depends on the immune response, the viral ge-
notype (low-risk or high-risk/oncogenic) and the site of
infection (the cervical squamo-columnar junction is more
susceptible to HPV disease). The key role of HPV in most
cancers of the female lower genital tract has been firmly
established biologically and epidemiologically23,41,45–47.
The cervical cancer is marked by a premalignant
phase of various grades of cervical intraepithelial neo-
plasm (CIN), which is a genetically unstable lesion and is
characterized by a spectrum of histological abnormali-
ties. HPV viral integration into the host genomic DNA is
associated with progressive genetic instability, and these
events play a fundamental role in the progression from
low-grade (CIN1) to high-grade (CIN2/3) lesions, and
eventually to invasive cervical cancer (ICC). In longitudi-
nal natural history studies, the elapsed time from the de-
tection of high-risk HPV to the development of CIN3 is
3–5 years45, and the progression to ICC takes a further
10–20 years47. Most cancers of the vulva and the vagina
in younger women are also induced by oncogenic HPV
types22,24. These cancers are preceded by both a high-
-grade vulvar intraepithelial neoplasia (VIN2/3) and vag-
inal intraepithelial neoplasia (VaIN2/3).
Molecular basis of HPV-induced oncogenesis
The HPV DNA usually exists as extrachromosomal
plasmid, mostly as a monomeric circular molecule in be-
nign cervical precursor lesions. However, in cervical can-
cer cells the HPV DNA is integrated into the host ge-
nome. During the HPV DNA integration, the viral geno-
me breaks in the E1/E2 region. The break leads to the
loss of E2, which encodes proteins including the one that
inhibits the transcription of the E6 and E7 regions, re-
sulting in the increased expression of E6 and E7 onco-
genic proteins48,49. The proteins coded by these genes are
multifunctional and interfere with important cell cycle
regulatory proteins. Expression of viral oncogenes is
tightly controlled in non-differentiated keratinocytes by
at least two signaling cascades, one operative at the func-
tional level and the other at the transcriptional level. In-
tegration of the viral DNA could occur, resulting in in-
creased expression of E6 and E7. Additionally, mutations
or methylation of host DNA could occur, abrogatingthe
transcriptional control of differentiation and viral gene
expression; there is evidence for both of these mecha-
nisms50,51. The oncoproteins E6 and E7 interact with
many cellular proteins and change fundamental cellular
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functions like cell cycle regulation, telomere mainte-
nance, susceptibility to apoptosis, intercellular adhesion,
and regulation of the immune response. These effects are
in accordance with the essential changes in cell physiol-
ogy that are acquired during tumor development and
that have been proposed by Hanahan & Weinberg52.
Evading the immune system surveillance has been recog-
nized as an additional basic feature of malignant growth53.
Regulation of the cell cycle
Maintenance of genetic integrity from one generation
to the next requires accurate replication of chromosomes
during the S-phase and their faithful segregation during
mitosis. Protein p53 is known as the »genome’s guard-
ian«54 and in case of DNA damage, p53 can provoke the
arrest of cellular division to assure the time necessary for
DNA repair.
If damage cannot be repaired, p53 is able to induce
the programmed cellular death (apoptosis) and prevent
the propagation of DNA damage in the subsequent gen-
eration of cells. The product of another tumor suppressor
gene, pRb acts as a repressor of E2F transcription fac-
tor55. E2F regulates various genes including those in-
volved in the progression of the cell cycle (the G1-S tran-
sition). By binding E2F, pRb prevents the entry into the
S-phase, providing the time necessary for checking ge-
nome integrity. Oncoproteins E6 and E7 cooperatively
disrupt the functions of p53 and pRb, with profound
changes in the cell cycle regulation56,57. Furthermore, E6
and E7 proteins can directly provoke DNA mutations of
the host cell58–60. As an aberration of virus infection, con-
stant activity of the viral proteins E6 and E7 leads to in-
creasing genomic instability, accumulation of gene muta-
tions, further loss of cell-growth control, and ultimately
cancer39,61.
Oncoprotein E6 functions
HPV 16 E6 is a 151 amino acid protein with two zinc
finger domains. E6 is one of the primary oncogenes of the
virus62, 63. E6 together with E7 causes immortalization of
cells and plays an important role in malignant transfor-
mation. Oncoprotein E6 interacts with numerous cellu-
lar proteins. E6 targets p53 through recruitment of a cel-
lular E3 ubiquitin ligase – E6 associated protein (E6AP).
This trimeric complex leads to p53 degradation by ubi-
quitin-proteosomal pathway. Besides targeting it for deg-
radation, E6 is capable of binding directly to p53, inter-
fering with its DNA-binding activity64. In addition, E6
protein blocks apoptosis, alters the transcription ma-
chinery, and disturbs intercellular interactions, a crucial
step towards malignancy. Another important target for
E6 is the group of PDZ proteins38. The name is related to
the first three members identified: PSD-95 (a post-syn-
aptic density signalling protein), Dlg (theDrosophila disc
large protein) and ZO1 (the zonula occludens 1 protein
with functional roles in epithelial polarity). Only high-
-risk E6 associates with PDZ proteins. These proteins
play an important role in cell signalling, cell adhesion,
and tight-junction integrity65. Experimental evidence in-
dicates that the interaction of E6 with PDZ proteins is
necessary for the development of epithelial hyperpla-
sia66.
Oncoprotein E7 functions
HPV 16 E7, a nuclear protein of 98 amino acids, has a
casein kinase II phosphorylation site at serine residues
31 and 3267. E7 interacts with various cellular proteins,
most of which are important regulators of the cell cycle,
especially the transition from the G1 to S-phase.
E7 proteins interact with the members of retinoblas-
toma protein family: pRb, p107, and p130 (also called
»pocket proteins«). Most of the pRb functions are related
to the repression of the E2F transcription factor. The E7
protein directly binds pRb and targets it for degradation
through the ubiquitin-dependant pathway68. Suppres-
sion of Rb function by E7 results in the activation of E2F
and stimulation of the cell cycle progression69. E7 is also
capable of a direct interaction with E2F factors and
chromatin modifiers, such as histone deacetylases (HDACs),
what additionally affects the expression of S-phase ge-
nes70,71. E7 protein interacts with cyclin dependent kin-
ases (CDK) inhibitors like p21 and p27. While E6 inhibits
p21 transcription by inactivating p53, E7 inhibits p21
functions by direct binding, thus contributing to sus-
tained activity of CDK, such as CDK2. High-risk E7 also
increases the expression of CDC25A phosphatase that
promotes CDK2 activation72. All these effects on cell pro-
liferation are not only favourable for the HPV life cycle
and replication, but they also contribute to the uncon-
trolled proliferation of infected cells. Besides disrupting
cell cycle control, and allowing the cell division in the
presence of DNA damage, E6 and E7 are capable of di-
rectly inducing DNA damage60. Thus, in HPV infected
cells a deleterious combination could be present: in-
creased DNA damage and impaired response to DNA
damage.
Telomere maintenance
While normal cells have finite numbers of doublings
before they become senescent (»Hayflick limit«), malig-
nant cells acquire limitless replicative potential52. The
immortality of malignant cells is closely related with
telomere maintenance52,73. The majority of malignant
cells achieve telomere maintenance by up-regulation of
telomerase, the enzyme that adds hexanucleotide repeats
to the 3’ end of DNA strands in the telomere regions.
Telomerase is a ribonucleoprotein complex containing
three subunits: a catalytic subunit – human telomerase
reverse transcriptase (hTERT), a RNA subunit and, a
protein subunit (dyskerin). The expression of hTERT is
proportional to telomerase activity in the cells. It has
been shown that high-risk E6 protein activates tran-
scription of hTERT. E6 interacts with Myc protein either
alone or in complex with E6AP74,75. Heterodimer Myc/
Max binds to the hTERT promoter and activates its tran-
scription. E6 also affects other hTERT activators includ-
ing Sp1, which binds to the hTERT promoter and histone
acetyltransferases that increase histone acetylation at
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the hTERT promoter76,77. E6 modulates activity of
hTERT repressors as well. The HPV 16 E6/E6AP com-
plex targets hTERT repressor X box-binding protein 1-91
(NFX1-91) for polyubiquitination and degradation. E6
affects the binding of two other hTERT repressors – up-
stream stimulating factors 1 and 2 (USF1 and USF2).
Additionally, E6 directly associates with NFX123 that in-
creases hTERT activity by several mechanisms including
those on transcriptional and post-translational level75. A
second mechanism of telomere maintenance is recombi-
nation-based and is termed alternative lengthening of
telomeres (ALT) pathway. It has been suggested that the
E7 protein affects telomere length through the ALT
pathway78. Thus, a cooperative effect between E6 and E7
could be achieved regarding telomere maintenance and
cell immortalization. The E7 effect could be important in
early cancer development while E6 might play a role in
the later phases of oncogenesis60. This is in accordance
with the observation that high levels of hTERT expres-
sion are found in advanced cervical lesions and invasive
carcinomas79.
Evading apoptosis
HPV has developed numerous mechanisms that block
host-mediated apoptosis. These mechanisms regulate the
survival of infected cells thus facilitating the HPV repli-
cation cycle. Besides blocking p53 function in regulation
of apoptosis, high-risk HPV proteins interact with both
extrinsic and intrinsic apoptotic pathways. The extrinsic
pathway is triggered by various extracellular signals that
activate »death receptors«, the members of the tumor ne-
crosis factor receptor (TNFR) family. After binding, the
ligand death receptors form trimers and associate with
adaptor molecules and initiator caspases. The result is
the formation of the death inducing signalling complex
(DISC). DISC activates caspase 8, which cleaves down-
stream caspases in the apoptotic pathway leading to cell
death. High-risk E6 protein interacts with all compo-
nents of the DISC complex. E6 binds to the death recep-
tor TNFR-1 and blocks its association with adapter mole-
cules80. Furthermore, E6 can accelerate the degradation
of some adapter molecules like FADD and the initiator
caspase-875,81. The intrinsic apoptotic pathway is acti-
vated by various intracellular stressors (DNA damage,
oxidative stress, and others) and includes mitochondrial
permeability transition. Then pro-apoptotic signals dom-
inate changes in mitochondrial membrane are initiated
with the formation of pores and release of pro-apoptotic
proteins. These proteins form an apoptotic signaling
complex that results in cleavage of downstream caspases
(like caspase-3 and caspase-7), leading to degradation of
cellular components. The E6 protein interacts with in-
trinsic apoptotic pathway signaling by binding Bak, a
pro-apoptotic member of Bcl-2 family. E6 binds Bak and
induces its degradation through the ubiquitin-protea-
some pathway82. The HPV E6 protein is also capable to
up-regulate the expression of inhibitors of apoptosis,
such as survivin and the inhibitor of apoptosis protein 2
(IAP2). The studies of HPV E7 in regulation of apoptosis
obtained variable results; both anti-apoptotic and pro-
-apoptotic effects have been found83. HPV oncoproteins
target a number of factors important for anoikis, a spe-
cific type of apoptosis that is induced by the loss of cell
adhesion or by inappropriate cell adhesion84,85. High-risk
HPV proteins bind to or are associated with changes in
expression levels of fibronectin, fibulin-1, focal adhesion
kinase (FAK), and paxillin60. These interactions contrib-
ute to the capability of HPV infected cells to become re-
sistant to anoikis and grow in the absence of anchorage
to the extracellular matrix and their neighbouring cells.
Anchorage independent growth is considered to be a hall-
mark of malignant phenotypes.
Escape from immune system surveillance
The major lines of defense against various pathogens
are natural mechanical barriers, innate and adoptive im-
munity. Dendritic cells (DC) are highly specialized anti-
gen presenting cells (APC) that play important roles in
innate immunity and provide a link between innate and
adoptive immunity. Toll-like receptors (TLR) located in
the membrane or inside the DC recognize typical molecu-
lar motifs of various pathogens called pathogen-associ-
ated molecular patterns (PAMPS). Langerhans cells are
the main DC of the skin and mucosa, being important de-
tectors at the site of HPV infection. Activated dendritic
cells migrate to draining lymph nodes, mature during the
migration to highly effective APC and present antigens
to naïve T lymphocytes, thereby initiating cell-mediated
responses. The activated effector (cytotoxic) cells target
infected cells at the site of infection4. Indeed, in case of
HPV infection in the majority of cases the virus is cleared
by cell-mediated mechanisms that are clinically associ-
ated with complete remission. However, the time neces-
sary for clearance ranges from months to years suggest-
ing a delay in immune response. 10–20% of infected
persons do not manage to clear the HPV infection and
develop persistent infection that is associated with the
risk of high-grade cervical lesions and invasive carcino-
ma86,87. HPV has developed several mechanisms for evad-
ing the immune surveillance. The majority of these me-
chanisms contribute to evading of innate immunity that
delays the adoptive immune response. Some of these
mechanisms are related with the characteristics of the
viral site of infection and some are related to the effects
of viral oncoproteins. HPV does not have a lytic phase,
and thereby does not cause cell injury that would initiate
inflammation and/or immune response. There is no vi-
raemic stage during HPV infection. Therefore both lo-
cally and systemically there is no favourable situation for
contact between HPV and the immune system. Hasan
and colleagues88 have shown that high risk E6 and E7
proteins inhibit TLR9 transcription leading to impaired
activation of the innate immune response. Additionally,
high-risk proteins interact with interferon regulatory
factors (IRF) required for the expression of type I inter-
ferons: E6 binds IRF-3 while E7 interacts with IRF-189,90.
Microarray analysis has shown that high-risk proteins
down-regulate the expression of IFN-inducible genes, in-
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cluding signal transducer and activator of transcription 1
(STAT1)91. One of the possible mechanisms that underlie
this phenomenon is a direct interaction of HPV 16 E7
with p48-the DNA binding component of the interferon-
-stimulated gene factor 3 (ISGF3) transcription com-
plexes, thus blocking the translocation of this complex to
the nucleus92. Furthermore, HPV proteins interact with
the proximal components of interferon-inducible path-
ways. E6 binds and inhibits the function of tyrosin ki-
nase (Tyk2), a component of the JAK-STAT signalling
pathway that mediates IFN cellular responses93. The ac-
tivity of another interferon-inducible double-stranded
RNA protein kinase (PKR) pathway is reduced by syner-
gistic action of E6 and E794. Activated PKR-phosphory-
lates multiple products lead to various antiviral effects
including the inhibition of translation. The reduced ac-
tivity of this pathway results in the maintenance of viral
protein synthesis. Furthermore, it has been shown that
interferon induced growth arrest depends on p53 acety-
lation. Post-transcriptional modifications, like acetyla-
tion, affect p53 stability and increase its transcriptional
activity. Besides reducing p53 availability by targeting it
for degradation, E6 interacts with p300/CBP that cata-
lyzes acetylation of p53. E6 forms a complex with p300/
CBP, thus preventing the acetylation of p5395. This mech-
anism might contribute to the proliferation of HPV in-
fected cells in the presence of interferon96.
Conclusions
The association between persistent HPV infection
and the risk of malignant transformation of the lower fe-
male genital tract is well established. HPV E6 and E7
oncoproteins are critical molecules in the process of ma-
lignant tumor formation. Interacting with various cellu-
lar proteins, E6 and E7 influence fundamental cellular
functions like cell cycle regulation, telomere mainte-
nance, susceptibility to apoptosis, intercellular adhesion,
and regulation of immune responses. High-risk E6 and
E7 cooperatively disrupt p53 and pRb functions with pro-
found changes in the cell cycle regulation. Uncontrolled
cell proliferation leads to increased risk of genetic insta-
bility; the generator of mutant phenotypes that will con-
tribute to conferring other abnormalities and possible
advantages for tumor growth. Furthermore, oncopro-
teins E6 and E7 are capable of directly provoking DNA
damage. It usually takes decades for cancer to arise.
Thus, cervical carcinogenesis is a multifactorial process
involving genetic, environmental, hormonal, and immu-
nological factors in addition to HPV infection.
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BOLESTI DONJEG DIJELA @ENSKOG SPOLNOG SUSTAVA POVEZANE S HUMANIM
PAPILOMAVIRUSOM – ONKOGENI ASPEKTI I MOLEKULARNE INTERAKCIJE
S A @ E T A K
Uzro~na veza infekcije humanim papilomavirusom (HPV) i karcinoma vrata maternice potvr|ena je biolo{ki i epide-
miolo{ki. Ve}ina karcinoma vulve i vagine tako|er su inducirani HPV-om. Infektivni ciklus zapo~inje kada virusne
~estice dospiju na bazalni sloj epitela gdje se ve`u i ulaze u stanice. Klju~ne molekule u procesu virusne replikacije su
virusni proteini E6 i E7. HPV tipovi visokog rizika blokiraju funkciju p53 proteina te djeluju na ekstrinzi~ne i intrin-
zi~ne puteve apoptoze. HPV koristi brojne mehanizme za izbjegavanje humanog imunolo{kog sustava i mijenja ekspre-
siju citokina putem E6 i E7 onkoproteina. Prosje~no 10 % inficiranih osoba razvije perzistentnu infekciju i upravo je ovo
rizi~na skupina za razvoj prekursorskih lezija visokog rizika i invazivnog karcinoma.
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